InvestSMART

Anatara Lifesciences Ltd (ASX: ANR) - Announcements

- Current share price for ANR : $0.010

ASX company news and announcements for Anatara Lifesciences Ltd (ANR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Anatara Lifesciences Ltd (ANR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Anatara Lifesciences Ltd (ANR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Anatara Lifesciences Ltd (ANR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Change in substantial holding from TEK 22 Nov 2024 5:09PM $0.058 $0.010 fallen by 82.76%
$3 Cleansing Notice 22 Nov 2024 11:11AM $0.058 $0.010 fallen by 82.76%
$3 Application for quotation of securities - ANR 22 Nov 2024 11:09AM $0.058 $0.010 fallen by 82.76%
$3 Change of Director's Interest Notice 20 Nov 2024 11:09AM $0.058 $0.010 fallen by 82.76%
$3 Notification regarding unquoted securities - ANR 18 Nov 2024 7:13PM $0.058 $0.010 fallen by 82.76%
$3 Update - Proposed issue of securities - ANR 15 Nov 2024 5:20PM $0.058 $0.010 fallen by 82.76%
$3 ANR Increase in Placement 15 Nov 2024 5:14PM $0.058 $0.010 fallen by 82.76%
$3 Proposed issue of securities - ANR 15 Nov 2024 12:11PM $0.059 $0.010 fallen by 83.05%
$3 Proposed issue of securities - ANR 15 Nov 2024 11:09AM $0.064 $0.010 fallen by 84.38%
$3 Proposed issue of securities - ANR 15 Nov 2024 11:00AM $0.064 $0.010 fallen by 84.38%
$3 Successful Placement of $660k and Share Purchase Plan 15 Nov 2024 10:59AM $0.064 $0.010 fallen by 84.38%
$3 Results of Meeting 14 Nov 2024 1:18PM $0.064 $0.010 fallen by 84.38%
$3 Chair's Address to Shareholders 14 Nov 2024 11:32AM $0.064 $0.010 fallen by 84.38%
$3 Trading Halt 13 Nov 2024 9:57AM $0.064 $0.010 fallen by 84.38%
$3 Pause in Trading 13 Nov 2024 9:49AM $0.064 $0.010 fallen by 84.38%
$3 Appendix 4C & Q1 FY25 Activities Report 31 Oct 2024 4:33PM $0.056 $0.010 fallen by 82.14%
$3 GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update 17 Oct 2024 8:21AM $0.050 $0.010 fallen by 80%
$3 GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update 8 Oct 2024 8:26AM $0.051 $0.010 fallen by 80.39%
$3 Appendix 4G and Corporate Governance Statement 2 Oct 2024 4:06PM $0.070 $0.010 fallen by 85.71%
$3 Annual Report to shareholders 2 Oct 2024 4:06PM $0.070 $0.010 fallen by 85.71%
$3 Notice of Annual General Meeting/Proxy Form 2 Oct 2024 4:04PM $0.070 $0.010 fallen by 85.71%
$3 European Patent Granted for GaRP Product Addendum 1 Oct 2024 10:17AM $0.070 $0.010 fallen by 85.71%
$3 Anatara's GaRP granted EU patent 20 Sep 2024 11:41AM $0.046 $0.010 fallen by 78.26%
$3 Anatara Annual General Meeting & Director Nominations 10 Sep 2024 7:20PM $0.044 $0.010 fallen by 77.27%
$3 GaRP Irritable Bowel Syndrome Clinical Trial Update 30 Aug 2024 8:12AM $0.046 $0.010 fallen by 78.26%

76 - 100 of 533 results

Page 4 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.